Tenaya Therapeutics Inc（TNYA）の株式分析TNYATenaya Therapeutics Inc

Tenaya Therapeutics, Inc. is a clinical-stage biotechnology company focused on discovering, developing, and delivering curative therapies that address the underlying drivers of heart disease. Its pipeline includes TN-201, TN-401, and TN-301. TN-201 is an adeno-associated virus serotype 9 (AAV9)-based gene therapy designed to deliver a working MYBPC3 gene to heart muscle cells via a single intravenous infusion, increasing MyBP-C protein levels to address the underlying cause of MYBPC3-associated HCM with the aim of halting or even reversing disease after a single dose. Its MyPEAK-1 Phase I b/2 clinical trial is an ongoing, multi-center, open-label, dose-escalating study designed to assess the safety, tolerability and clinical efficacy of a one-time intravenous infusion of TN-201 gene replacement therapy. TN-401 is its AAV9-based gene therapy being developed for the treatment of arrhythmogenic right ventricular cardiomyopathy (ARVC) due to disease-causing variants in the PKP2 gene. It operates in the Healthcare sector (BIOLOGICAL PRODUCTS, (NO DISGNOSTIC SUBSTANCES) industry).

Tenaya Therapeutics Inc is not a good buy right now. The stock is currently trading at $0.361, which is very close to its 52-week low of $0.36. The RSI is at a low 23.328, indicating that the stock is oversold, but this could also suggest a continued downward trend. Additionally, the company has reported significant losses, with a net income loss of $43,393,000 in Q2 2026, and a gross margin of only 100% in the most recent quarters, which is not sustainable. The stock has declined 73.84% over the past year, and insider selling has increased by 55,373.56% in the last month, indicating a lack of confidence from those within the company. The main risk is the company's ongoing financial losses and the potential for further declines in stock price.